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INTERAKSI ANTARA SISTEM SARAF SIMPATETIK DAN RENIN 
ANGIOTENSIN KE ATAS HEMODINAMIK GINJAL DALAM 
KEGAGALAN GINJAL, HIPERTENSI DAN GABUNGAN KEGAGALAN 
GINJAL DAN HIPERTENSI 
 
ABSTRAK 
 
Adrenoseptor α1 dan reseptor subjenis angiotensin jenis 1 (AT1) memainkan peranan 
penting dalam pengawalaturan hemodinamik. Aktiviti simpatetik yang melampau 
ialah punca penyakit yang selalu menyebabkan kegagalan ginjal kepada komplikasi 
yang seterusnya. Kajian ini membincangkan peranan fungsi adrenoseptor α1 dan 
reseptor subjenis angiotensin jenis 1 (AT1) dalam pengantaraan pengecutan salur 
darah berintangan di dalam hemodinamik ginjal untuk penyakit kegagalan ginjal, 
hipertensi dan gabungan kedua-dua keadaan patologikal dengan penumpuan kepada 
interaksi antara sistem saraf simpatetik (SNS) dan sistem renin angiotensin (RAS). 
Tikus normotensif WKY dan hipertensi SHR telah digunakan. Kegagalan ginjal 
diaruhkan dengan cisplatin (5 mg/kg i.p). Tikus-tikus WKY dan SHR tanpa 
kegagalan ginjal dan kegagalan ginjal dibahagikan mengikut rawatan awalan 
masing-masing iaitu kawalan, denervasi oleh 6OHDA, losartan (10 mg/kg/day) 
(LOS) dan gabungan 6OHDA dan losartan (6OHDALOS). Losartan diberikan secara  
oral selama 7 hari sebelum kajian akut. Berat badan, jumlah air yang diminum, 
jumlah pengeluaran air kencing, kandungan natrium dan kreatinin dalam air kencing  
dan plasma, penyingkiran kreatinin, perkumuhan terpecah natrium dan indeks bacaan  
ginjal diukur. Dalam kajian akut, tikus-tikus ini dibiuskan dengan menggunakan 
natrium pentobarbiton (60 mg/kg i.p) untuk pengukuran tekanan darah dan 
pengaliran darah ginjal. Pengurangan pengaliran darah ginjal terhadap rangsangan 
elektrik saraf ginjal, pemberian noradrenalina, fenilefrina, metoksamina dan 
angiotensin II secara intra ginjal ditentukan. Data dirakam dengan menggunakan 
sistem perolehan data berkomputer dan diekspresikan sebagai purata ± s.e.m serta 
xx 
 
dianalisakan dengan ANOVA dua hala diikuti dengan post-hoc Bonferroni pada 
tahap signifikasi 5 %. Pengurangan secara signifikan dalam berat badan dan jumlah 
air yang diminum, peningkatan dalam jumlah pengeluaran air kencing dan 
perkumuhan terpecah natrium serta pengurangan terhadap penyingkiran kreatinin 
telah didapati dalam tikus dengan kegagalan ginjal. Dari respon vasokonstriktor 
ginjal, saraf ginjal yang sempurna sangat penting dalam pengawalaturan 
hemodinamik ginjal. Didapati bahawa fungsi adrenoseptor α1B / α1D dalam interaksi 
silang positif dengan reseptor AT1 dipengaruhi dengan kuat oleh simpatektomi dan 
losartan. Tambahan lagi, sekatan terhadap RAS telah menghasilkan interaksi positif 
dengan SNS. Kajian ini mengukuhkan lagi fakta yang menyatakan aktiviti simpatetik 
yang terlampau yang berlaku dalam tikus yang berpenyakit dan keadaan ini lebih 
teruk dalam tikus yang mempunyai penyakit berganda. Lagipun di bawah pengaruh 
kegagalan ginjal dan hipertensi, terdapat perubahan sumbangan fungsi subjenis 
adrenoseptor α1 dalam keadaan aktiviti simpatetik yang terlampau. Kesimpulannya, 
kajian ini mencadangkan kemungkinan wujud hubungan silang yang positif antara 
adrenoseptor α1 dan reseptor AT1 dan hubungan ini amat dipengaruhi oleh keadaan 
patologi kegagalan ginjal dan hipertensi.  
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INTERACTION OF SYMPATHETIC NERVOUS SYSTEM AND RENIN 
ANGIOTENSIN SYSTEM IN RENAL HAEMODYNAMICS OF RENAL 
FAILURE, HYPERTENSIVE AND RENAL FAILURE HYPERTENSIVE 
RATS 
 
ABSTRACT 
 
α1-adrenoceptors and angiotensin type 1 (AT1) receptor subtypes play a key role in 
the regulation of renal haemodynamics. Sympathetic overactivity is the common 
pathogenesis that aggravates renal failure into further complications. This study 
discusses the functional role of α1-adrenoceptors and AT1 receptor in mediating the 
vasoconstriction of renal resistance vessels in renal haemodynamics of renal failure, 
hypertension and combination of both pathological states emphasizing on the 
interaction between sympathetic nervous system (SNS) and renin-angiotensin system 
(RAS). Normotensive WKY and hypertensive SHR were utilized. Cisplatin (5 mg/kg 
i.p) was used to induce renal failure. Non-renal failure and renal failure WKY and 
SHR were grouped according to their pre-treament which were control, denervation 
by 6-hydroxydopamine (6OHDA), losartan (10 mg/kg/day) (LOS) and a combination 
of losartan and 6OHDA (6OHDALOS). Losartan was given orally for 7 days prior to 
the acute study. Body weight, water intake, urine output, urine and plasma sodium, 
creatinine clearance, fractional excretion of sodium and kidney index were measured. 
In acute study, the animals were anesthetized (60 mg/kg i.p. sodium pentobarbitone) 
for blood pressure and renal blood flow (RBF) measurements. Reductions in RBF to 
electrical stimulation of renal nerve and intrarenal administration of noradrenaline, 
phenylephrine, methoxamine and angiotensin II were determined. Data were 
recorded using a computerized data acquisition system and expressed as mean ± 
s.e.m and analysed by 2-way ANOVA followed by Bonferronni post-hoc test with a 
significance level at 5%. Significant reductions in the body weight and water intake, 
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increased urine output and fractional excretion of sodium as well as a marked 
decrease in the creatinine clearance were observed in the renal failure rats. From the 
renal vasoconstrictor responses, an intact renal nerve is very important in regulation 
of renal haemodynamics. It seems that functionality of α1B / α1D adrenoceptors in the 
positive crosstalk with AT1 receptor was greatly influenced by sympathectomy and 
losartan. Furthermore blockade of RAS produced a positive interaction with SNS. 
This study further supported that the fact there is exaggerated sympathetic activity in 
diseased animals and its severity increases in multiple diseased states. Moreover, 
under the influence of renal failure and hypertensive conditions, there was a shift in 
functional contributions of α1 adrenoceptors subtype in enhanced sympathetic 
conditions. Collectively it is suggested that there was a positive crosstalk relationship 
between 1- adrenoceptors and AT1 receptors, and this is greatly influenced by the 
pathological conditions of renal failure and hypertension. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 The kidney  
1.1.1 Basic anatomy 
The kidneys are retroperitoneal organs, meaning they lie against the posterior 
abdominal wall just behind the peritoneum and can be found on each side of the 
spine, specifically located between 12
th
 thoracic and 3
rd
 lumbar vertebrae. They are 
partially secured by the lower ribs, closely held by a connective tissue renal fascia 
and is surrounded by a thick layer of adipose tissue called perirenal fat. The kidneys 
are roughly bean shape with an indentation called the hilum, where the renal artery 
enters while the renal vein and ureter leave the kidney. Kidney has a granular 
appearance. Each kidney is enclosed in a fibrous capsule and composed of cortex and 
inner medulla.  The cortex and medulla form the parenchyma, which is the functional 
tissue of the kidney (Applegate, 2000).  
 
The functional units in the kidney are nephrons. There are over a million nephrons in 
each kidney. Each nephron consists of a renal corpuscle, an initial filtering 
component and renal tubule. Kidneys’ granular-like appearance is due to the renal 
corpucles that are located in the cortex of the kidney. The renal corpuscle filters 
blood free from cells and proteins by its component, the glomerulus, a compact tuft 
of interconnected capillary. The glomeruli are surrounded by a fluid-filled capsule 
called Bowman’s capsule. Blood enters the glomerulus via afferent arterioles and 
leaves through efferent arterioles. As blood flows throughout the glomerulus, a 
portion of plasma is filtered into Bowman’s capsule, which is continuous with the 
renal tubule. Reabsorbtion or excretion process occurs as the filtrate flows all the 
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way through the tubules. Ultimately, all the fluid from all the nephrons exit the 
kidneys as urine. The very narrow hollow renal tubules consist of three different 
regions which are proximal convoluted tubule, loop of Henle and distal convoluted 
tubule. Drains from the Bowman’s capsule are the highly coiled proximal convoluted 
tubule. The next portion is loop of Henle which is the sharp hairpin-like loop 
consisting of a descending and ascending limb leading to the next tubular segment, 
the distal convoluted tubule (Applegate, 2000; Vander et al., 2001). 
 
From the nephrons, urine flow into collecting duct. The distal convoluted tubules 
from various nephrons join with each collecting duct. All the way from Bowman’s 
capsule to the collecting duct system, each nephron is completely separate from the 
others. This separation ends when multiple collecting ducts merge into the minor 
calyces that surround the renal papillae. Then the completed urine draws off into the 
kidney’s central cavity, the renal pelvis that is continuous with ureter draining the 
contents into the bladder (Applegate, 2000; Vander et al., 2001). 
 
1.1.1a Juxtaglomerular apparatus 
Areas near the end of ascending limb of nephron loop that are continuous with distal 
convoluted tubule converge with glomerular afferent arterioles of that nephron. At 
this point the cells of the ascending limb are modified into macula densa and those in 
the wall of the afferent arteriole are modified to form the juxtaglomerular cells. The 
combination of both cells makes up the juxtaglomerular apparatus where their 
function is to secrete renin and monitors blood pressure (Applegate, 2000). 
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1.1.2 Renal functions 
First and foremost, the kidneys are one of the decisive organs of fluid balance. This 
is because they precisely regulate very hard to keep the balance among the water 
concentration, inorganic-ion composition and volume of the internal environment in 
the body. Secondly, the kidney is responsible for removal of metabolic waste 
products such as urea, uric acid, creatinine and many others from the blood into the 
urine as quickly as they are produced. This is to prevent the toxic waste products 
from being accumulated in the body. Next is the elimination of the foreign chemicals 
like drugs, pesticides, food additives and their metabolites from the blood and urine. 
Fourth, kidneys are accountable for gluconeogenesis. Gluconeogenesis is a 
biochemical process where glucose, the source of energy synthesised from non-
carbohydrate source like amino acids. Ultimately, the kidneys function as endocrine 
glands. They secrete three hormones. These are erythropoietin, renin and 1, 25-
dihydroxyvitamin D3 (Vander et al., 2001). 
 
1.1.3 Renal haemodynamics  
Blood flows through the kidney at an approximate rate of 1200 millimeters per 
minute. Renal arteries are branched from abdominal aorta. They carry about 20-25% 
of total resting cardiac output (5 L/min) into the kidney which is about 1.2 L/min 
(Murphy and Robinson, 2006). At the hilum, the renal arteries are divided into 
segmental arteries that pass through the renal sinus. Segmental arteries are bifurcated 
into interlobular arteries, traverse the renal column and split to form arcuate arteries, 
which pass over the base of the pyramids. Subsequently, arcuate arteries divide into 
interlobular arteries that extend to the cortex of the kidney and ascend to the afferent 
arterioles. From the afferent arterioles, the blood enters the capillaries in the 
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glomerulus and finally exit through efferent arterioles. The renal circulation consist 
of two sets of arterioles (afferent and efferent arterioles) and two sets of capillaries 
that are glomerulus and peritubular capillaries. The afferent arterioles are also known 
as preglomerular arterioles that divide into the tangled capillary network, glomerulus, 
which then coalesce to form the efferent arterioles (postglomerular arterioles). Next, 
each of efferent arteriole diverges to develop an extensive capillary network, called 
peritubular capillaries around the tubular region (proximal and distal convoluted 
tubules) of the nephron or form a long hairpin loop of capillaries, known as vasa 
rectae. Vasa rectae is another part of peritubular capillaries that loop deep down to 
medulla alongside the loop of Henle. Eventually, the peritubular capillaries reunite to 
form interlobular veins. From there, the blood flows through the arcuate veins, 
interlobular veins, segmental veins and into renal veins, which return the blood to the 
inferior vena cava (Ganong, 1999; Applegate, 2000).  Approximately, 90% of the 
renal blood flow remains in the renal cortex and perfuses the peritubular capillaries. 
The remaining 10% of the blood flow perfuses the renal medulla via vasa rectae 
(Kriz, 1981; Zimmerhackl et al., 1987; Cupples et al., 1988).   
 
Intrarenal haemodynamics determine the construction of glomerular filtrate, the 
reabsorbtion of fluid by peritubular capillaries and the maintenance of a 
hyperosmotic medullary environment (Arendshorst and Navar, 2001). There are 
several factors either intrinsic or extrinsic to the kidneys that regulate the renal blood 
flow. Those major mechanisms intrinsic to kidney are the autoregulatory mechanism, 
intrarenal renin-angiotensin mechanism, renal prostaglandin or eicosanoids and 
kinins while the extrinsic factors are such as circulating vasoactive agents namely 
nitric oxides (NO), purinergic agents such as ATP and adenosine, other peptide 
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hormones including endothelin and atrial natriuretic peptide (ANP) and renal 
sympathetic nerve activity (Arendshorst and Navar, 2001). 
 
1.1.4 Renal autoregulation  
Autoregulation can be experimentally defined by a rapidly-acting mechanism by the 
vascular bed to functionally maintain its perfusion constant from perturbation of 
blood pressure that may cause an acute change in renal blood flow (RBF) and 
glomerular filtration rate (GFR) (Loutzenhiser et al., 2006). This function is present 
in almost all tissues but is particularly pronounced in some organs, such as brain and 
kidney (Just, 2007). One of the most striking criteria of the renal circulation is the 
competency of the kidney to maintain a constant RBF and GFR as perfusion pressure 
fluctuates (Loutzenhiser et al., 2006). There is accrued evidence, which indicates that 
autoregulatory response plays a concurrent role in protecting the kidney from 
hypertensive injury (Bidani and Griffin, 2004; 2002). Evidence suggests that in the 
presence of intact autoregulation, less injury happens in spite of substantial 
hypertension. Conversely, susceptibility to hypertensive renal damage is greatly 
increased and injury with even moderate hypertension is seen when there is 
diminished autoregulatory response. Moreover, when the renal autoregulation is 
impaired, there is no evidence of disturbed volume regulation. This shows that intact 
renal autoregulation is not an obligate requirement for adequate volume control but it 
is important for normal renal protection (Loutzenhiser et al., 2006).  
 
Autoregulation of renal blood flow (RBF) has long been recognized. RBF 
autoregulation is believed to be mediated by two mechanisms, the renal myogenic 
response (MR) and the tubulo-glomerular feedback (TGF). These two mechanisms 
6 
 
either act in concert or differently in their primary role to stabilize renal function by 
preventing pressure-induced fluctuations in RBF, GFR and the delivery of filtrate to 
the distal tubule (distal delivery). The current view is that when accentuation of 
blood pressure occurs, these two mechanisms act parri passu to achieve a precise 
regulation of GFR and RBF (Loutzenhiser et al., 2006). 
 
Myogenic response (MR) involves a direct vasoconstriction of the afferent arteriole 
in response to stretching forces. A rise in intra-luminal pressure induces 
vasoconstriction in vascular smooth muscle. This effect prevails over the passive 
distension of the elastic vascular wall and also reduces the diameter of small 
resistance vessels below the one at lower pressure. This causes an increased vascular 
resistance at higher pressure, thus allowing autoregulation to take place (Just, 2007). 
It has been suggested that the primary purpose of MR is to protect the kidney against 
the damaging effects of hypertension. This is due to its kinetic attributes which allow 
the afferent arterioles to sense elevations in the rapidly oscillating systolic BP and 
adjust tone to this signal. Nevertheless this postulation deserves critical evaluation 
(Loutzenhiser et al., 2006).   
 
Tubuloglomerular feedback (TGF) is a more complicated mechanism specific to the 
kidney. Macula densa senses a flow-dependent signal and alters tone in the adjacent 
segment of afferent arteriole via a mechanism that likely involves adenosine and/or 
ATP (Castrop et al., 2004(a); Insco et al., 2003; Sun et al., 2001). This leads the 
afferent arterioles to contract in response to an increase in the sodium chloride 
(NaCl) concentration at the macula densa in the early distal tubule (Komlosi et al., 
2005; Schnermann et al., 1998). At the ascending part of Henle’s Loop, the 
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reabsorption of salts is active and is a rate-limited process. The concentration of 
NaCl reaching the macula densa is dependent on the tubular flow rate. Enhanced 
tubular flow in response to an increase in arterial pressure raises the NaCl 
concentration at macula densa, thus causing vasoconstriction of afferent arteriole. 
These actions provide restoration of filtration and autoregulation of RBF (Just, 
2007). 
 
It is thought today, perhaps a third regulatory mechanism, that is independent of TGF 
but slower than MR, also contributes to a smaller extent of role in mediating renal 
autoregulation (Just, 2007). However, much less is known about the contribution of 
the third additional mechanism. Since the detection of the third regulating 
mechanism has been complicated due to difficulty in eliminating MR without 
affecting TGF, Just and Arendshorst (2003) suggested an alternative approach, that 
is, by distinguishing between the responsible mechanisms based on their dynamics 
and relative contributions. In the experimental setup, continuous inhibition of TGF 
by furosemide, it can be seen that based on the response times, the primary increase 
in renal vascular resistance (RVR) is due to action of MR and secondary to TGF. It 
also establishes evidence for a slow third regulatory component (Just, 2007; Just and 
Arendshorst, 2003). However, the underlying nature of the third mechanism awaits 
further investigation although possibilities may include angiotensin II (Ang II) 
(Cupples, 1993), ATP acting on P2X1 and slow TGF-independent regulation 
reflecting a slow component of MR (Just, 2007). Several reports have suggested that 
the third regulatory element is more readily noticeable and more significant at lower 
pressures than at resting pressure levels which are relatively small and depending on 
the complete inhibition of TGF. This element may represent either a fading 
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vasodilator or an accumulating constricting substance with rising renal arterial 
pressure (RAP) (Just and Arendshorst, 2003). Other important findings were, in the 
absence of TGF, both the strength and speed of the MR were augmented indicating a 
negative interaction linking TGF and MR. The enhancement and its acceleration lead 
to a more rapid achievement of the steady-state level of autoregulation (Just and 
Arendshorst, 2003). 
 
Other regulatory mechanisms may slightly play essential roles in RBF autoregulation 
which might impair rather than support the maintenance of a constant flow of blood 
by vascular bed. They also may impinge on overall renal function through 
modulation of MR or TGF (Just, 2007). 
 
The relative contribution of the responsible mechanisms was estimated based on 
initial changes in renal vascular resistance (RVR) which represent that MR is 
considerably faster than TGF and the third regulatory mechanism (Just and 
Arendshorst, 2003). In the kidney vasculature, MR requires less than 10 seconds for 
completion of autoregulatory action. The total response time of TGF is 30-60 
seconds and the third regulatory component may contribute 30-60 seconds for the 
overall autoregulation of RBF (Just, 2007). Consequently in the study by Just and 
Arendshorst (2003), they conclude RBF autoregulation is mediated by each of the 
triumvirate: MR, TGF, and the ill-defined third regulatory mechanism are 55%, 35-
45% and 0-12% respectively in response to a rise in renal arterial pressure (RAP) 
whilst 73%, 18-27% and 0-9% correspondingly during response to falling RAP in 
euvolemic rat. The rationale behind this remains open for exploration. Due to 
differences in their response time (kinetic differences), the speed of the overall 
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autoregulation can get affected. Their relative contributions determine the size and 
range of pressure fluctuation reaching glomeruli, peritubular capillaries and 
medullary perfusion, which therefore will impact on filtration, reabsorption, and 
hypertensive renal damage (Just and Arendshorst, 2003).   
 
The balance among the triumvirate contributing to RBF autoregulation can be 
influenced by the interaction between them and subjected to modulation, most likely 
by Ang II and nitric oxide (NO). A positive interaction has been observed where 
activation of TGF causes vasoconstriction on its own and induces the autoregulatory 
vasoconstrictor response of MR (Schnermann and Briggs, 1989). Whereas, inhibition 
of TGF might not only impair the autoregulation in the segment immediately 
affected by TGF but also in upstream part of the vascular tree (Moore and Casellas, 
1990).  
  
Ang II is a strong modulator of TGF. It is a very potent vasoconstrictor and has a 
strong effect on the baseline level of RBF. Yet the steady-state autoregulation is 
neither affected by Ang II infusion (Kiil et al., 1969) and antagonism by angiotensin 
converting enzyme inhibitor (ACEi) (Arendshorst and Finn, 1977; Hall et al., 1979; 
Persson et al., 1988) nor Ang II receptor antagonists (Hall et al., 1979; Persson et al., 
1988). It also does not influence the balance of each triumvirate contribution of MR, 
TGF and the third regulatory mechanism (Just, 2007).    
 
Nitric oxide (NO) strongly modulates TGF by its attenuating influence on the 
vasoconstrictor response elicited by high tubular perfusion rates or NaCl 
concentration. Nevertheless it does not affect TGF at low perfusion rates (Ito and 
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Ren, 1993). There is evidence that the speed of MR is accelerated in the absence of 
NO (Just and Arendshorst, 2005). The nature of this underlying mechanism is still in 
ambiguity. For the predominance of MR during inhibition of NO, it is suggested that 
MR might naturally dominate the autoregulatory function due to the speed and 
upstream location to TGF and the third regulatory mechanism. Therefore, it can 
minimize any error signal from reaching the latter mechanisms (Just, 2007). Despite 
a strong and continuous vasodilator influence of endogenous NO on baseline RBF, 
steady-state autoregulation is typically not affected by inhibition of NO production 
(Baumann et al., 1992; Beierwaltes et al., 1992; Majid and Navar, 1992).  
 
In summary, RBF autoregulation is primarily mediated by rapid MR and TGF, 
contributing ~50% and 35-50% respectively and even more sluggish third regulatory 
mechanism appears to contribute < 15% at resting arterial pressure (Just, 2007; Just 
and Arendshorst, 2003). 
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1.2 Acute renal failure 
Acute renal failure (ARF) can be characterized as an abrupt deterioration of the 
glomerular filtration rate (GFR) over a period of hours to days resulting in the failure 
of the kidney to excrete neither nitrogenous (urea and creatinine) nor non-
nitrogenous waste products and to maintain fluid and electrolytes homeostasis 
(Lameire et al., 2005).  
 
Acute renal failure (ARF) is a common complication of critical illness and occurs 
anywhere depending on the population being studied and the criteria used to define 
its presence. Due to extensively contrasting definitions of ARF, trials of prevention 
and therapies are not parallel and hence, have complicated the research about ARF 
(Bellomo et al., 2004; Mehta et al., 2007). It is increasingly recognized to be a broad 
clinical entity rather than a specific diagnosis (Murphy and Robinson, 2006). There 
are more than 30 separate definition of ARF found in the literature that is 
objectionable. ARF definition can range from severe to slight increases in serum 
creatinine concentration. Therefore a practical definition of ARF is acute and 
sustained increase in serum creatinine concentration of 44.2 μmol/ L if the baseline is 
less than 221 μmol/ L, or an increase in serum creatinine concentration of more than 
20% if the baseline is more than 221 μmol/ L ( Singri et al., 2003).   
 
A multilevel definition and classification in a recent attempt at defining renal failure 
has been advocated by the Acute Dialysis Quality Initiative group viz. the RIFLE 
system (http://www.ccforum.com/content/8/4/R204) (Figure 1.1), which uses a 
combination of creatinine and urine output compared with baseline measurements. 
These measurements define three severity categories whether the patient is at risk, 
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has an injury, has failure and two clinical outcomes loss of function, or is at end-
stage kidney disease (ESKD). The purpose of this is to acknowledge the important 
adaptations that happen in ESKD but not in persistent ARF. Persistent ARF (loss) 
mean necessitation for renal replacement therapy (RRT) for more than 4 weeks 
whilst ESKD is defined by dialysis requirement for longer than 3 months (Bellomo et 
al., 2004).  
 
 
Figure 1.1: Proposed classification scheme for acute renal failure (ARF). The 
classification system includes separate criteria for creatinine and urine output (UO). 
A patient can fulfill the criteria through changes in serum creatinine (SCreat) or 
changes in UO, or both. The criteria that lead to the worst possible classification 
should be used. Note that the F component of RIFLE (Risk of renal dysfunction, 
Injury to the kidney, Failure of kidney function, Loss of kidney function and End-
stage kidney disease) is present even if the increase in SCreat is under threefold as 
long as the new SCreat is greater than 4.0 mg/dl (350 μmol/l) in the setting of an 
acute increase of at least 0.5 mg/dl (44 μmol/l). The designation RIFLE-FC should be 
used in this case to denote 'acute-on chronic' disease. Similarly, when the RIFLE-F 
classification is achieved by UO criteria, a designation of RIFLE-FO should be used 
to denote oliguria. The shape of the figure denotes the fact that more patients (high 
sensitivity) will be included in the mild category, including some without actually 
having renal failure (less specificity). In contrast, at the bottom of the figure the 
criteria are strict and therefore specific, but some patients will be missed. *GFR = 
Glomerular Filtration Rate; ARF= Acute Renal Failure (Adapted from Bellomo et 
al., 2004).  
Urine Output Criteria GFR Criteria* 
Risk 
Injury 
Failure 
Loss 
ESKD 
High  
Specificity 
End Stage Kidney Disease 
(>3months) 
Persistent ARF*=complete loss of kidney 
function >4weeks 
Increased SCreatx1.5 or 
GFR decrease >25% UO<.5ml/kg/h x 6hr 
Increased SCreatx2 or 
GFR decrease >50% UO<.5ml/kg/h x 12hr 
Increased SCreatx3or 
GFR decrease >75% 
OR SCreat >4mg/dl 
Acute rise >0.5mg/dl 
UO<.5ml/kg/h x 24hr or  
Anuria x 12hrs 
(Oliguria) 
High  
Sensitivity 
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Traditionally, classifications of ARF aetiologies have been identified as prerenal, 
postrenal and intrinsic renal azotaemia (Figure 1.2). Prerenal azotaemia (acute 
prerenal failure) is a physiological response to renal hypoperfusion which leads to a 
reduction in GFR. In the prerenal form, there is a reversible increase in serum 
creatinine and blood urea concentrations. It contributes 30-60% of all cases of ARF 
and is frequently community-acquired especially affecting aged population. In this 
acute prerenal failure, the integrity of the renal tissue is preserved. However it can 
complicate any disease characterized by either true hypovolaemia or a reduction in 
the effective circulating volume viz. low cardiac output, systemic vasodilation or 
intrarenal vasoconstriction (Lameire et al., 2005). Persistent renal hypoperfusion 
may progress into ischemic acute tubular necrosis. Prerenal azotaemia and ischemic 
acute tubular necrosis are part of a continuum of renal hypoperfusion and together 
account for 75% of the cases of acute renal failure (Lameire et al., 2005; 2004).  
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Figure 1.2: Classification and major causes of acute renal failure. NSAIDs = non-
steroidal anti-inflammatory agents, ACE = angiotensin converting enzymes (Adapted 
from Lameire et al., 2005). 
 
Postrenal azotaemia (postrenal acute renal failure) occurs when there is obstruction 
of the urinary collection system or extrarenal drainage by either intrinsic or extrinsic 
masses. Obstructive uropathy particularly affects older men with prostatic disease 
and patients with a single kidney or intra-abdominal cancer particularly pelvic cancer 
(Bhandari et al., 1995; Chapman et al., 1991). The vital sequelae of postrenal acute 
renal failure are the post obstructive diuresis and the presence of hyperkalaemic renal 
tubular acidosis (Yarger, 1992). Moreover, postrenal ARF only account 1-10% of 
hospital-acquired ARF (Lameire et al., 2005; 2004).  
 
The major cause of intrinsic renal azotaemia is acute tubular necrosis (ATN) 
although acute vascular, glomerular and interstitial processes may also cause intrinsic 
ACUTE RENAL FAILURE 
PRERENAL  INTRINSIC RENAL POSTRENAL  
Absolute decrease in 
effective blood 
volume 
• Haemorrhage 
• Volume depletion 
 
Relative decrease in 
blood volume 
(ineffective arterial 
volume) 
• Congestive heart     
failure 
• Decompensated liver 
cirrhosis 
 
Arterial 
occlusion/stenosis of 
renal artery 
Haemodynamic form 
• NSAIDs 
• ACE inhibitors or 
angiotensin II receptor 
antagonist 
Vascular Acute 
glomerulonephritis 
Acute 
Interstitial 
nephritis 
Acute 
tubular 
necrosis 
Obstuction of 
collecting system or 
extrarenal drainage 
ischaemic nephrotoxic 
Exogenous 
•Antibiotics 
(gentamicin) 
•Radio 
contrast agent 
•cisplatin 
Endogenous 
• Intratubular 
pigment 
• Intratubular 
protein 
• Intratubular 
crystal 
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ARF. ATN is caused by ischemic or nephrotoxic injury to the kidney in 50% and 
35% of all hospital- acquired ARF respectively.  There is 30-50% established 
decrease of RBF in clinical ATN. The pathophysiology of ATN involves the vascular 
and tubular components (Lameire, 2005).  
 
1.2.1 Vascular component      
In most of experimental animals, acute ischemic injury has been shown to be 
associated with a loss of renal autoregulation (Conger et al., 1988). In normal 
autoregulatory response, renal vasodilatation by the vasodilating product of 
arachidonic acid (prostaglandin) and nitric oxide will try to counterattack with the 
decrease in renal perfusion pressure. However the ischemic kidney is associated with 
renal vasoconstriction (Schrier, 2004). Renal vasoconstriction occurs as a result of an 
increase in afferent and efferent arteriolar vascular resistance, reduced glomerular 
plasma flow and a decrease in glomerular hydrostatic pressure (Conger, 2001). 
Enhanced renal sympathetic tone has been observed in the setting of ischemic and 
nephrotoxic ATN. Moreover, the vasoconstrictor response to exogenous 
norepinephrine and circulating vasoconstrictors such as catecholamine, angiotensin II 
and endothelin has been shown to be augmented in the acute ischemic insult. These 
renal vascular abnormalities are related to the resultant increase in cytosolic calcium 
observed in the afferent arterioles of the glomerulus. Therefore, administration of 
calcium channel blockers may reverse the loss of autoregulation, thus reducing the 
renal dysfunction of the acute ischemic kidney (Conger et al., 1988). 
 
Outer medullary congestion of the kidney is another vascular hallmark of acute renal 
ischaemia by worsening the relative hypoxia in the outer medulla (S3, segment of the 
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proximal tubule and the thick ascending limb of the loop of Henle) (Mason et al., 
1984). Endothelial damage due to increase oxidant injury is also associated with 
acute renal ischemia which eventually may enhance the renal vasoconstrictor effect 
of circulating pressor agents present in ARF. Oxidant injury results in decreased 
endothelial nitric oxide synthase (eNOS) and prostaglandins but leads to increase in 
endothelin (Molitoris et al., 2002). The defence action by vasodilating 
pharmacological manoeuvres returns the renal blood flow to normal level but GFR 
continues to fall (Lameire and Vanholder, 2004; Schrier et al., 2004). 
 
1.2.2 Tubular component 
There are three aspects of tubular abnormalities: structural changes, tubular 
obstruction and tubuloglomerular balance and tubular fluid backleak in ischemic 
acute renal failure. As for structural changes, ARF that is characterized by tubular 
dysfunction with impaired sodium and water reabsorption is correlated with the 
shedding and excretion of proximal tubule brush border membranes and epithelial 
tubule cells into the urine (Thadani et al., 1996). Abnormalities in the proximal 
tubule cytoskeleton are associated with translocation of Na+/K+-ATPase from the 
basolateral to the apical membrane. This has been shown by in vitro studies using 
chemical anoxia (Molitoris et al., 1989). Na+/K+-ATPase facilitates vectorial 
sodium transport, thus its translocation by hypoxia or ischemia impedes the tubular 
sodium reabsorption in ARF (Schrier et al., 2004).  
 
There are potential pathways through which the loss of brush border membranes, loss 
of viable and non-viable proximal tubule cells and less proximal tubule sodium 
reabsorption may lead to diminished GFR during ARF. Brush borders that detach 
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from the basement membrane and the cellular debris may contribute to the 
intraluminal aggregation of cells and protein resulting in tubular obstruction 
(Thadani et al., 1996) (Figure 1.3). The occurrence of the obstructing cast may 
explain the dilation of the tubules including collecting duct that have been revealed 
upon the renal biopsy of ARF kidneys albeit GFR is less than 10% of normal 
(Schrier et al., 2004). However, this remains open for discussion whether tubular 
obstruction by cast is alone sufficient in reducing GRF correlated with clinical ARF. 
Moreover, some micropuncture studies have shown that with normal tubular and 
glomerular pressure, formerly obstructing luminal cast can be dislodged by the 
proximal tubular flow rate in a single nephron whilst improved GFR in the same 
nephron (Conger et al., 1984). Besides, during ischemic insult the cellular adhesions 
of viable cells into the other tubular cells and extracellular matrix also happen to 
cause tubular obstruction. This adherence involving integrin-mediated adhesion 
molecules via binding to Arg-Gly-Asp (RGD) sequences. Thereby lesser tubular 
obstruction was seen and increase in proximal tubular pressure has been reversed in 
reperfusion period after synthetic cyclical RGD being induced (Noiri et al., 1994). 
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Figure 1.3: Tubular changes in the pathophysiology of ischaemic acute tubular 
necrosis. After ischaemia and reperfusion, morphological changes occur in the 
proximal tubules, including loss of polarity, loss of the brush border, and 
redistribution of integrins and sodium/potassium ATPase to the apical surface. 
Calcium and reactive oxygen species also have roles in these morphological changes, 
in addition to subsequent cell death resulting from necrosis and apoptosis. Both 
viable and non-viable cells are shed into the tubular lumen, resulting in the formation 
of casts and luminal obstruction and contributing to the reduction in the GFR 
(Reproduced with permission from Thadani et al., 1996). 
 
Based on foregoing discussion of renal autoregulation, TGF will be activated when 
there is any alteration in the sodium chloride (NaCl) delivery at the macula densa. In 
acute ischemic kidney, less proximal tubular sodium reabsorption will increase the 
NaCl concentration to the macula densa, thus allowing the vasoconstriction of the 
glomerular arteriole which enhances the sensitivity of TGF and decreases GFR in 
patients with clinical ARF (Schnermann, 2003). An abrupt fall of GFR in ARF can 
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be explained by the combination of both tubular cast formation and activation of the 
tubuloglomerular feedback mechanism that is concurrent to the ARF-related decrease 
in proximal tubular sodium reabsorption. Positively, decrease in GFR while ischemic 
insult attenuates the demand for ATP-dependent tubular reabsorption due to less 
NaCl released to damage tubules (Schrier et al., 2004).  
 
Tubular fluid backleak into the circulation can occur as a result of loss of tubular 
epithelial cell barrier and/or the tight junctions between viable cells in acutely 
ischemic kidney (Molitoris et al., 1989) thus providing false interpretation of low 
GFR especially to non-reabsorbable substances such as inulin in inulin clearance. 
However, glomerular filtrates seep out rarely observed with clinical ARF in human 
except in cadaveric transplanted kidneys with delayed graft function (Edelstein and 
Schrier, 2001).    
 
Inflammation has a major role in the pathogenesis of decreased GFR associated with 
ischemic ARF (Lameire et al., 2005; Schrier et al., 2004).  Contribution of inducible 
nitric oxide synthase (iNOS) in ARF has been experimentally approved in Western 
Blot analysis of ischemic kidney homogenates where there is a profound increase in 
the iNOS protein expression. Moreover blockage of the upregulation of iNOS by the 
antisense oligonucleotide was shown to protect the kidney from ischemic insult 
(Noiri et al., 1996). Peroxynitrite as a product of NO scavenging by oxygen radicals 
can cause tubular damages during ischemia (Noiri et al., 2001).  
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The other causes of acute renal failure include sepsis, hypovolaemia, pre-existing 
renal impairment, and nephrotoxins such as aminoglycoside antibiotics and 
radiological contrast agents (Uchino et al., 2005; 2004) 
 
Acute renal failure is associated with a significant risk of mortality and morbidity. 
Due to modern renal replacement modalities, there is an insistent belief that acute 
renal failure (ARF) presents a rather harmless complication and that survival is 
determined by the severity of the underlying disease process/accompanying 
complications but not by renal dysfunction per se. However the evidence from the 
experimental and recent research shows the opposite outcomes where ARF presents a 
condition which exerts a fundamental impact on the course of the disease, the 
advancement of associated complications and on prognosis, independently from the 
type and severity of the underlying disease (Druml, 2004). ARF carries an 
independent risk of death that patients are rather dying “of” than “with” ARF 
(Kellum and Angus, 2002). 
 
ARF is not restricted to kidney disease only, but it is a systemic disease that affects 
all physiologic functions and organ systems of the body (Druml, 2004). Systemic 
effects of ARF are manifolds. After several hour of ARF induction, there is increase 
in the gene expression in experimental animals, non-renal tissues and other organs 
e.g. lung, activation of circulating immunocompetent cells (Rabb et al., 2000) and 
increase in vascular-permeability for proteins and alveolar micro-haemorrhage 
mediated by neutrophils (Kramer et al., 1999). Furthermore, ARF can result in 
pulmonary oedema, increase levels of tumour necrosis factor (TNF)-alpha, 
interleukin-1 (IL-1) and intercellular adhesion molecule-1 mRNA in the heart 
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associated with functional changes in the heart 24 hours after renal ischemia such as 
increase in the left ventricular end-diastolic and systolic diameter. Even unilateral 
renal ischemia causes inflammation and injury in the contralateral kidney (Meldrum 
et al., 2002).  
Table 1.1: Pathophysiologic consequences of acute renal failure. 
Cardiovascular  Hypercirculation, cardiomyopathy, pericarditis 
Pulmonary  Lung edema, alveolitis, pneumonia, pulmonary hemorrhage 
Gastrointestinal Impairment of motility, erosions, ulcerations, hemorrhage, 
pancreatitis, colitis  
Neuromuscular Neuropathy, myopathy, encelopathy 
Immunologic Impairment of humoral and cellular immunity and 
immunocompetence 
Hematologic Anemia, thrombocytopenia hemorrhagic diathesis 
Metabolic Insulin resistance, hyperlipidaemia, activation of protein 
catabolism, depletion of antioxidants 
 
(Adapted from Druml, 2004) 
 
These multiple systemic consequences of ARF (Table 1.1) are mediated by the 
acutely uremic state per se (“uremic intoxication”), by immunomodulatory effects 
radiating from the injured organ kidney and by side effects associated with renal 
replacement therapies. The kidneys in ARF initially are mostly “victims” of a 
systemic disease process, such as a shock state or sepsis. Nevertheless, as the acutely 
uremic state induces negative repercussions on the organism, the kidneys become 
“offenders” (Druml, 2004). 
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1.2.3 Cisplatin induced acute renal failure 
Cisplatin is one of the most remarkable successes in 'the war on cancer.' It is the most 
potent chemotherapeutic drug and the most widely used for the treatment of several 
human malignancies. It reveals one of the highest cure rates, over 90% in testicular 
cancers. Cisplatin-based combination chemotherapy regimens and related platinum-
based therapeutics are currently used as front-line therapy in the treatment of 
testicular cancer, head and neck, ovarian, cervical, bladder, non-small cell lung 
carcinoma, and many other types of cancer (Pabla and Dong, 2008; Wang and 
Lippard, 2005; Cohen and Lippard, 2001; Arany and Safirstein, 2003; Siddik, 2003).  
Escalation of its dose significantly improves its therapeutic effects. However, to 
maximize its antineoplastic effects by using high-dose therapy with cisplatin is 
hindered due to its cumulative side effects in normal tissues and organs, notably its 
nephrotoxicity in the kidneys (O’Dwyer et al., 1999). Its use is mainly limited by two 
factors: acquired resistance to cisplatin and severe side effects in normal tissues, 
which include neurotoxicity, ototoxicity, nausea, hearing loss, vomiting, and 
nephrotoxicity (Loehrer and Einhorn, 1984; Ward and Fauvie, 1977; Pabla and 
Dong, 2008). Still, cisplatin is the drug of choice in many platinum-based therapy 
regimens and remains one of the most regularly used chemotherapeutic drugs 
(Hanigan and Devarajan, 2003). 
 
It has long been recognized that nephrotoxicity induced by cisplatin can result in 
severe nephropathy leading to acute renal failure (Thadani et al., 1996; Kang et al., 
2004; Kawai et al., 2006). Prevalence of cisplatin nephrotoxicity is high, occurring in 
about one-third of patient whereby having transient elevation of blood urea nitrogen 
levels or other evidence of kidney damage in the days following cisplatin treatment 
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(Meyer and Madias, 1994; Beyer et al., 1997; Arany and Safirstein, 2003). Within 
48–72 hours of cisplatin administration, decreased glomerular filtration rate has been 
shown (Winston and Safirstein, 1985). Clinically, cisplatin nephrotoxicity is often 
seen after 10 days of cisplatin administration. It is manifested as severe reduction in 
the glomerular filtration rate, higher serum creatinine, severe reduction in the 
creatinine clearance, increased fractional excretion of sodium, increased kidney 
index, a variable fall in the renal blood flow and reduced serum magnesium and 
potassium levels, (Kang et al., 2004; Lameire, 2005; Arany and Safirstein, 2003). 
The long-term effects of cisplatin on renal function may lead to subclinical but 
permanent reduction in glomerular filtration rate (Brillet, 1994).
  
 
Cisplatin is known to accumulate in mitochondria of renal epithelial cells (Singh 
1989; Gemba and Fukuishi, 1991). Consequently, complex signaling pathways will 
be activated when tubular cells are exposed to cisplatin, thus leading to tubular cell 
injury and death. Meanwhile, stimulated robust inflammatory response occurs, 
further exacerbating renal tissue damage. Cisplatin may also induce injury in renal 
vasculature and result in decreased blood flow and ischemic injury of the kidneys, 
contributing to a decline in glomerular filtration rate. These events act in concert, 
culminating in the loss of renal function during cisplatin nephrotoxicity and 
triggering acute renal failure (Figure 1.4).  
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Figure 1.4: Overview of the pathophysiological events in cisplatin nephrotoxicity. 
Cisplatin enters renal cells by passive and/or facilitated mechanisms. Exposure of 
tubular cells to cisplatin activates signaling pathways that are cell death promoting 
(MAPK, p53, ROS, and so on) or cytoprotective (p21). Meanwhile, cisplatin induces 
TNF-  production in tubular cells, which triggers a robust inflammatory response, 
further contributing to tubular cell injury and death. Cisplatin may also induce injury 
in renal vasculature, leading to ischemic tubular cell death and decreased glomerular 
filtration rate (GFR). Together, these pathological events culminate in acute renal 
failure (Adapted from Pabla and Dong, 2008).  
 
The acute renal failure caused by cisplatin in rat exhibits alterations in renal tubular 
epithelial structure. Renal tubular cells suffer a continuum of cytotoxic injuries, 
ranging from mild sublethal changes to a catastrophic necrotic death characterized by 
swelling and rupture of cells and activation of an inflammatory response (Thadani et 
al. 1996). There are at least two distinct mechanisms that may be responsible for 
renal tubular cell death:  cell death in the form of both necrosis and apoptosis (Pabla 
and Dong, 2008).  It is suggested that the dosage of cisplatin might determine 
whether the cells die due to necrosis or apoptosis. While extensive injury with  a high 
concentration of cisplatin (millimolar) can lead to necrotic cell death, less severe 
renal injuries associated with lower concentrations of cisplatin (micromolar) leads to 
